ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
35.62
0.96%
US Tech 100
18,064.80
0.02%
S&P 500
5,277.51
0.80%
US Dollar vs CAD
1.36525
0.00%
Bitcoin
67,636.15
-0.13%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Ocugen Inc (OCGN)

  7. Ocugen Inc (OCGN) News

OCGN

Ocugen (OCGN)

Ocugen Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:OCGN
DateTimeSourceHeadlineSymbolCompany
05/31/20247:36AMGlobeNewswire Inc.Data and Safety Monitoring Board Approves Simultaneous Enrollment in Cohort 3 and Phase 2 Initiation in OCU410 ArMaDa study for Geographic AtrophyNASDAQ:OCGNOcugen Inc
05/29/20246:15AMGlobeNewswire Inc.Ocugen to Present at BIO International Convention 2024NASDAQ:OCGNOcugen Inc
05/28/20243:05PMEdgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:OCGNOcugen Inc
05/28/20246:02AMGlobeNewswire Inc.Ocugen Set to Join Russell 3000® Index Effective June 28, 2024NASDAQ:OCGNOcugen Inc
05/20/20246:00AMGlobeNewswire Inc.Ocugen Announces CSO to Present on Modifier Gene Therapy at International Society for Cell & Gene Therapy 2024NASDAQ:OCGNOcugen Inc
05/17/20243:30PMEdgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:OCGNOcugen Inc
05/15/20245:30AMGlobeNewswire Inc.Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene TherapyNASDAQ:OCGNOcugen Inc
05/14/20242:54PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:OCGNOcugen Inc
05/14/20247:00AMGlobeNewswire Inc.Ocugen Provides Business Update with First Quarter 2024 Financial ResultsNASDAQ:OCGNOcugen Inc
05/14/20246:18AMIH Market NewsUS Futures Remain Steady Amid Wall Street Caution Ahead of April PPI ReportNASDAQ:OCGNOcugen Inc
05/14/20245:32AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:OCGNOcugen Inc
05/10/20243:15PMEdgar (US Regulatory)Form 8-A12G - Registration of securities [Section 12(g)]NASDAQ:OCGNOcugen Inc
05/10/20243:14PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:OCGNOcugen Inc
05/10/20243:05PMGlobeNewswire Inc.Ocugen Announces Distribution of Series C Preferred Stock to Holders of its Common StockNASDAQ:OCGNOcugen Inc
05/10/20246:45AMGlobeNewswire Inc.Ocugen to Present at May 2024 Investor ConferencesNASDAQ:OCGNOcugen Inc
05/03/20246:30AMGlobeNewswire Inc.Ocugen to Host Conference Call on Tuesday, May 14 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2024 Financial ResultsNASDAQ:OCGNOcugen Inc
05/02/20246:15AMGlobeNewswire Inc.Ocugen Announces CSO to Present on Modifier Gene Therapy at Retina World CongressNASDAQ:OCGNOcugen Inc
04/29/20245:45AMGlobeNewswire Inc.Ocugen Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024NASDAQ:OCGNOcugen Inc
04/26/20248:05AMGlobeNewswire Inc.UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual MeetingNASDAQ:OCGNOcugen Inc
04/26/20245:30AMGlobeNewswire Inc.Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual MeetingNASDAQ:OCGNOcugen Inc
04/19/20246:13AMGlobeNewswire Inc.Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene TherapyNASDAQ:OCGNOcugen Inc
04/12/20246:30AMGlobeNewswire Inc.Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital MarketsNASDAQ:OCGNOcugen Inc
04/10/20246:02AMGlobeNewswire Inc.Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa IndicationNASDAQ:OCGNOcugen Inc
04/08/20245:30AMGlobeNewswire Inc.Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial — First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa IndicationNASDAQ:OCGNOcugen Inc
04/05/20246:02AMGlobeNewswire Inc.Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410—a Modifier Gene Therapy—in Phase 1/2 ArMaDa Study for Geographic AtrophyNASDAQ:OCGNOcugen Inc
04/02/20247:00AMGlobeNewswire Inc.Ocugen Provides Business Update with Certain Financials for the Year Ending 2023NASDAQ:OCGNOcugen Inc
04/01/20245:08PMGlobeNewswire Inc.Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410ST—a Modifier Gene Therapy—in GARDian Study for Stargardt DiseaseNASDAQ:OCGNOcugen Inc
04/01/20244:43PMGlobeNewswire Inc.Ocugen to Host Conference Call on Tuesday, April 2 at 8:30 A.M. ET to Provide Business Update with Certain Financials for the Year Ending 2023NASDAQ:OCGNOcugen Inc
03/18/20245:30AMGlobeNewswire Inc.Ocugen, Inc. Appoints Huma Qamar, MD, MPH as Chief Medical OfficerNASDAQ:OCGNOcugen Inc
03/13/20247:00AMGlobeNewswire Inc.Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410NASDAQ:OCGNOcugen Inc
 Showing the most relevant articles for your search:NASDAQ:OCGN

Your Recent History

NASDAQ
MDLZV
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved